New drug cocktail shows promise for tough lung cancer
NCT ID NCT04958811
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of three drugs—tiragolumab, atezolizumab, and bevacizumab—in people with advanced non-squamous non-small cell lung cancer that has already been treated. The goal is to see if the combination can shrink tumors or slow disease progression. About 29 participants will receive the drugs every three weeks, and researchers will monitor response rates and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tiragolumab, atezolizumab, and bevacizumab (immune-boosting and anti-angiogenesis drugs)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced non-squamous lung cancer that has stopped responding to prior therapy.
- What could go wrong
- This is a small, early-phase (phase 2) study with only 29 participants, so results may not apply broadly. The drug combination can cause significant immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a novel drug combo outperform standard chemo for lung cancer?
- Can a Four-Drug cocktail shrink Hard-to-Treat lung tumors?
- New lung cancer drug aims to match Keytruda's success
- Targeted drug shows promise for Gene-Driven lung cancers
- Engineered virus plus immunotherapy aims to outperform chemo in advanced lung cancer
- New drug duo aims to tackle Hard-to-Treat cancers